Table 3

Expected probabilities of response by outcome for key comparators

Intervention*Probability of response, median (95% credible interval)
PASI 75PASI 90Resolution of enthesitisResolution of dactylitisDiscontinuation due to AEs
Brodalumab 210 mg70.3% (62.3, 77.4)52.7% (44, 61.3)38% (24.9, 52.6)53.6% (38.5, 70.6)1.4% (0.2, 7.2)
Ixekizumab 80 mg every two weeks67% (57.8, 75.5)49% (39.4, 58.9)40.5% (26.7, 56.3)59.8% (36.3, 77.4)3.9% (1, 14.5)
Ixekizumab 80 mg every four weeks†63.1% (55.4, 70.3)44.9% (37.1, 52.7)33.1% (21.5, 46.8)63.2% (41.7, 78.2)2.1% (0.6, 7.8)
Secukinumab 150 mg†53.2% (45.7, 59.5)35% (28.3, 41.1)41.6% (29.6, 53.7)50.5% (35.8, 67.2)2.3% (0.6, 8.2)
Secukinumab 300 mg†63.7% (56.3, 69.5)45.4% (37.9, 51.9)44.4% (32, 56.7)62.4% (47.4, 77.1)1.9% (0.6, 6.5)
Guselkumab 100 mg every eight weeks‡76.6% (68.5, 82.2)60.3% (50.7, 67.5)42.3% (28.1, 56.3)60.4% (42.4, 73.8)1.9% (0.4, 8.4)
Tildrakizumab 100 mg every twelve weeks40.2% (25.5, 55.1)23.7% (13, 36.8)11.8% (0.4, 98.3)
Ustekinumab 45 mg‡60% (52.8, 67.8)41.6% (34.6, 49.9)32.9% (21.1, 49.9)43.9% (29.5, 62.2)0.6% (0.1, 2.9)
Ustekinumab 90 mg54.8% (46.6, 63)*36.5% (29.1, 44.8)*40.4% (27.2, 57.9)†46.8% (32, 65)†0.7% (0.1, 3.2)
Adalimumab 40 mg every two weeks†44.2% (36.9, 50.7)27% (21.2, 32.8)39.7% (27.6, 52.6)51.3% (33.3, 68.1)3.8% (1.2, 11.8)
Certolizumab 200 mg every two weeks42.2% (31, 53)25.4% (16.8, 34.8)5.2% (0.7, 36.8)
Certolizumab 400 mg every four weeks41.5% (30, 53.3)24.8% (16.1, 35.2)8.2% (1.2, 47.4)
Etanercept 50 mg once weekly26.1% (15.4, 42.2)13.5% (6.8, 25.4)2.6% (0.1, 48.7)
Etanercept 50 mg +MTX 20 mg once weekly3.3% (0.1, 56.7)
Etanercept 50 mg twice weekly33.9% (20.1, 52.5)18.9% (9.6, 34.3)4.2% (0.1, 63.1)
Golimumab 50 mg43.5% (32.1, 58.4)26.5% (17.6, 40)0.8% (0.1, 6.4)
Golimumab 100 mg55.7% (44, 69.6)37.4% (26.9, 52)0.8% (0.1, 6.4)
Infliximab 5 mg/kg65.8% (54.7, 78)47.7% (36.4, 62)8.2% (1.3, 47)
Infliximab 5 mg/kg+MTX 15 mg12.4% (0.2, 89.9)
Abatacept 125 mg‡16.3% (10.4, 23.9)7.4% (4.2, 12)33.9% (20, 51.8)43.1% (25.2, 62.3)0.6% (0, 7.2)
Placebo†9.7% (3.4, 22)3.9% (1.1, 10.8)23% (12.7, 37.8)31.1% (11, 62.3)2.4% (0.8, 7.1)
  • *Key comparators include bDMARDs at doses licensed for use in PsA or PsO.

  • †Based on a combination of studies reporting outcomes at week 12 or 16 and week 24.

  • ‡Based on studies reporting outcomes at week 24 only bDMARD.

  • AE, adverse event; bDMARD, biological disease-modifying antirheumatic drug; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis.